ArticleJournal of virology2025
Characterization of quasispecies of severe fever with thrombocytopenia syndrome virus.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multidimensional mechanisms of SFTSV-host interactions: viral protein functions, mFrontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Three specific amino acid variations have been identified in the quasispecies of the isolated YG1 strain of severe fever with thrombocytopenia syndrome virus (SFTSV): Gn (Y328H), Gc (R624W), and L (N1891K). The Gn (Y328H) accounted for 26.9% of the viruses in the patient's blood. The other two mutations are less frequent, indicating that these mutations appeared during propagation in Vero E6 cells. To investigate the effects of each mutation on viral properties, we evaluated viruses with one to three mutations. Mutations Y328H and R624W in glycoprotein (GP) resulted in increased plaque size and cell fusion activity. Viruses with the N1891K mutation in L showed a notable cytopathic effect (CPE), which was inhibited by a pan-caspase inhibitor, suggesting that caspase-dependent cell death occurred. Programmed cell death-associated caspases were induced in both CPE-inducing and wild-type virus-infected cells. Furthermore, infection with the wild-type virus suppressed actinomycin D-induced cell death. These results suggest that SFTSV-infected cells initiate programmed cell death, whereas the wild-type virus inhibits cell death. Additionally, the recombinant single mutant virus outcompeted by a 10-fold lower amount of the wild-type virus in Vero E6 cells, indicating that the mutations were not advantageous for viral propagation in Vero E6 cells. These findings suggest that the quasispecies composition of SFTSV is influenced by the propagative environment.IMPORTANCEThis study presents findings on viral pathogenesis by analyzing quasispecies derived from a fatal case of severe fever with thrombocytopenia syndrome virus (SFTSV) infection. Analysis of recombinant SFTSV with mutations in Gn and Gc suggested that combinations of mutations may enhance the viability of mutant viruses, thereby selecting viruses to create a suitable population for propagation. The N1891K mutation in the L protein of SFTSV is associated with promoting cytopathic effects (CPE). Conversely, the wild-type virus, which is the predominant virus in infected patients, suppresses cell death. It has been suggested that SFTSV possesses a mechanism to evade cell death for prolonged viral propagation within the infected cells. Although the precise mechanism remains unknown, RNA virus polymerase may be involved in regulating cell death. This study contributes to our understanding of the mechanisms underlying the adaptation and survival of viruses as quasispecies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.